Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Infantile Spasms Therapeutics Market by Type (Oral, Injection, Infantile Spasms Therapeutic), By Application (Hospital, Clinic) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Infantile Spasms Therapeutics Market by Type (Oral, Injection, Infantile Spasms Therapeutic), By Application (Hospital, Clinic) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 171375 3300 Pharma & Healthcare 377 233 Pages 4.7 (39)
                                          

Market Overview:


The global infantile spasms therapeutics market is expected to register a CAGR of 7.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing incidence of infantile spasms, rising awareness about available treatment options, and growing demand for oral therapies. Based on type, the global infantile spasms therapeutics market is segmented into oral therapies and injection therapies. Oral therapies are further classified into anticonvulsants and corticosteroids. Injection therapies are further classified into adrenocorticotropic hormone (ACTH) therapy and vigabatrin therapy. Among these segments, the oral anticonvulsant segment is expected to account for a major share of the global infantile spasms therapeutics market in 2018. This can be attributed to factors such as rising prevalence of epilepsy in children and increasing adoption of oral anticonvulsants over other treatment options owing to their better safety profile and fewer side effects as compared with injectable medications. Based on application, the global infantile spasms therapeutics market is segmented into hospitals and clinics.


Global Infantile Spasms Therapeutics Industry Outlook


Product Definition:


Infantile spasms is a rare seizure disorder that affects infants and young children. It is characterized by sudden, repetitive muscle contractions called spasms. These spasms can cause the child to stiffen or curl up into a ball. Infantile spasms usually begin before the age of 1 year and often stop by age 5.


Oral:


Oral is a drug that is administered by mouth. It may enter the body in various ways such as through injection, inhalation, or absorption through the skin. The drug may be prescribed for spasms and rigidity associated with infantile epilepsy and cerebral palsy. Infantile spasms are also known as “fits” or “epilepsy” of which there are two types: generalised (or simple) fits and partial seizures (or complex).


Injection:


Injection is a drug delivery system that involves the administration of drugs into the body. Injectables can be divided into two major categories, including semi-synthetic and fully synthetic. Semi-synthetic injectables are made from ingredients found in nature; these include anesthetics, anti-inflammatory drugs such as corticosteroids and immunosuppressants such as methotrexate.


Application Insights:


The hospital application segment dominated the global infantile spasms therapeutics market in 2017. This can be attributed to a large patient base and high prevalence of neurological disorders. According to the data published by WHO, in 2016, about 300 million people around the world suffered from some form of epilepsy with 50 million individuals being diagnosed with this condition every year. Similarly, as per Epilepsy Foundation India¢â‚¬â„¢s 2015 statistics, about 40 million people are living with epilepsy worldwide while 2.5 million are diagnosed with this condition annually thus presenting an ample opportunity for lucrative growth over the forecast period for clinics and hospitals involved in its treatment.


Regional Analysis:


North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing government funding for infantile spasms research, rising awareness about infantile spasms treatment, and availability of highly effective drugs. In addition, high cost of these medicines in the region may act as a barrier for many families seeking treatment but it has been found that Infant Spasm Relief (ISR) tablets generic version costs around half as much as brand name counterpart and works just as well.


Growth Factors:


  • Increasing incidence of infantile spasms
  • Rising awareness about infantile spasms and its treatment options
  • Growing number of research studies on infantile spasms
  • Availability of new and innovative therapies for infantile spasms
  • increasing funding for research on infantile spasms

Scope Of The Report

Report Attributes

Report Details

Report Title

Infantile Spasms Therapeutics Market Research Report

By Type

Oral, Injection, Infantile Spasms Therapeutic

By Application

Hospital, Clinic

By Companies

Mallinckrodt, H. Lundbeck, Insys Therapeutics, Orphelia Pharma, Valerion Therapeutics, Catalyst Pharmaceuticals, Anavex Life Sciences, Retrophin, GW Pharmaceuticals, Infantile Spasms Therapeutic

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

233

Number of Tables & Figures

164

Customization Available

Yes, the report can be customized as per your need.


Global Infantile Spasms Therapeutics Market Report Segments:

The global Infantile Spasms Therapeutics market is segmented on the basis of:

Types

Oral, Injection, Infantile Spasms Therapeutic

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Clinic

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Mallinckrodt
  2. H. Lundbeck
  3. Insys Therapeutics
  4. Orphelia Pharma
  5. Valerion Therapeutics
  6. Catalyst Pharmaceuticals
  7. Anavex Life Sciences
  8. Retrophin
  9. GW Pharmaceuticals
  10. Infantile Spasms Therapeutic

Global Infantile Spasms Therapeutics Market Overview


Highlights of The Infantile Spasms Therapeutics Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Oral
    2. Injection
    3. Infantile Spasms Therapeutic
  1. By Application:

    1. Hospital
    2. Clinic
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Infantile Spasms Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Infantile Spasms Therapeutics Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Infantile spasms is a rare, life-threatening disorder of the nervous system that affects infants and young children. The cause is unknown, but it may be caused by a combination of genetic and environmental factors. Infantile spasms can cause uncontrolled muscle contractions in the body, leading to difficulty breathing and death if not treated quickly. There is currently no cure for infantile spasms, but treatments are available that help improve symptoms.

Some of the major players in the infantile spasms therapeutics market are Mallinckrodt, H. Lundbeck, Insys Therapeutics, Orphelia Pharma, Valerion Therapeutics, Catalyst Pharmaceuticals, Anavex Life Sciences, Retrophin, GW Pharmaceuticals, Infantile Spasms Therapeutic.

The infantile spasms therapeutics market is expected to grow at a compound annual growth rate of 7.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Infantile Spasms Therapeutics Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Infantile Spasms Therapeutics Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Infantile Spasms Therapeutics Market - Supply Chain
   4.5. Global Infantile Spasms Therapeutics Market Forecast
      4.5.1. Infantile Spasms Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Infantile Spasms Therapeutics Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Infantile Spasms Therapeutics Market Absolute $ Opportunity

5. Global Infantile Spasms Therapeutics Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Infantile Spasms Therapeutics Market Size and Volume Forecast by Type
      5.3.1. Oral
      5.3.2. Injection
      5.3.3. Infantile Spasms Therapeutic
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Infantile Spasms Therapeutics Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Infantile Spasms Therapeutics Market Size and Volume Forecast by Application
      6.3.1. Hospital
      6.3.2. Clinic
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Infantile Spasms Therapeutics Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Infantile Spasms Therapeutics Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Infantile Spasms Therapeutics Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Infantile Spasms Therapeutics Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Infantile Spasms Therapeutics Demand Share Forecast, 2019-2026

9. North America Infantile Spasms Therapeutics Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Infantile Spasms Therapeutics Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Infantile Spasms Therapeutics Market Size and Volume Forecast by Application
      9.4.1. Hospital
      9.4.2. Clinic
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Infantile Spasms Therapeutics Market Size and Volume Forecast by Type
      9.7.1. Oral
      9.7.2. Injection
      9.7.3. Infantile Spasms Therapeutic
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Infantile Spasms Therapeutics Demand Share Forecast, 2019-2026

10. Latin America Infantile Spasms Therapeutics Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Infantile Spasms Therapeutics Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Infantile Spasms Therapeutics Market Size and Volume Forecast by Application
      10.4.1. Hospital
      10.4.2. Clinic
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Infantile Spasms Therapeutics Market Size and Volume Forecast by Type
      10.7.1. Oral
      10.7.2. Injection
      10.7.3. Infantile Spasms Therapeutic
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Infantile Spasms Therapeutics Demand Share Forecast, 2019-2026

11. Europe Infantile Spasms Therapeutics Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Infantile Spasms Therapeutics Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Infantile Spasms Therapeutics Market Size and Volume Forecast by Application
      11.4.1. Hospital
      11.4.2. Clinic
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Infantile Spasms Therapeutics Market Size and Volume Forecast by Type
      11.7.1. Oral
      11.7.2. Injection
      11.7.3. Infantile Spasms Therapeutic
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Infantile Spasms Therapeutics Demand Share, 2019-2026

12. Asia Pacific Infantile Spasms Therapeutics Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Infantile Spasms Therapeutics Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Infantile Spasms Therapeutics Market Size and Volume Forecast by Application
      12.4.1. Hospital
      12.4.2. Clinic
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Infantile Spasms Therapeutics Market Size and Volume Forecast by Type
      12.7.1. Oral
      12.7.2. Injection
      12.7.3. Infantile Spasms Therapeutic
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Infantile Spasms Therapeutics Demand Share, 2019-2026

13. Middle East & Africa Infantile Spasms Therapeutics Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Infantile Spasms Therapeutics Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Infantile Spasms Therapeutics Market Size and Volume Forecast by Application
      13.4.1. Hospital
      13.4.2. Clinic
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Infantile Spasms Therapeutics Market Size and Volume Forecast by Type
      13.7.1. Oral
      13.7.2. Injection
      13.7.3. Infantile Spasms Therapeutic
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Infantile Spasms Therapeutics Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Infantile Spasms Therapeutics Market: Market Share Analysis
   14.2. Infantile Spasms Therapeutics Distributors and Customers
   14.3. Infantile Spasms Therapeutics Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Mallinckrodt
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. H. Lundbeck
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Insys Therapeutics
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Orphelia Pharma
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Valerion Therapeutics
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Catalyst Pharmaceuticals
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Anavex Life Sciences
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Retrophin
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. GW Pharmaceuticals
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Infantile Spasms Therapeutic
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us